ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
0
views
0
references
Top references
cited by
51
Cite as...
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
4,426
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Human papillomavirus vaccines. WHO position paper.
Author(s):
WHO
Publication date:
2009-04-10
Journal:
Relevé épidémiologique hebdomadaire / Section d'hygiène du Secrétariat de la Société des Nations = Weekly epidemiological record / Health Section of the Secretariat of the League of Nations
Keywords:
Condylomata Acuminata
,
prevention & control
,
Cost-Benefit Analysis
,
Female
,
Humans
,
Male
,
Papillomaviridae
,
immunology
,
Papillomavirus Infections
,
economics
,
epidemiology
,
Papillomavirus Vaccines
,
administration & dosage
,
therapeutic use
,
World Health Organization
Read this article at
ScienceOpen
PubMed
Review
Review article
Invite someone to review
Bookmark
Cite as...
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
EPJ Photovoltaics
Author and article information
Journal
PubMed ID::
19360985
ScienceOpen disciplines:
Chemistry
Keywords:
Condylomata Acuminata
,
prevention & control
,
Cost-Benefit Analysis
,
Female
,
Humans
,
Male
,
Papillomaviridae
,
immunology
,
Papillomavirus Infections
,
economics
,
epidemiology
,
Papillomavirus Vaccines
,
administration & dosage
,
therapeutic use
,
World Health Organization
Data availability:
ScienceOpen disciplines:
Chemistry
Keywords:
Condylomata Acuminata
,
prevention & control
,
Cost-Benefit Analysis
,
Female
,
Humans
,
Male
,
Papillomaviridae
,
immunology
,
Papillomavirus Infections
,
economics
,
epidemiology
,
Papillomavirus Vaccines
,
administration & dosage
,
therapeutic use
,
World Health Organization
Comments
Comment on this article
Sign in to comment
Similar content
4,426
The Key Differences between Human Papillomavirus-Positive and -Negative Head and Neck Cancers: Biological and Clinical Implications
Authors:
Steven F Powell
,
Lexi Vu
,
William C. Spanos
…
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer
Authors:
T Y Seiwert
,
C. Foster
,
E. A. Blair
…
Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus–Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy
Authors:
C Tsai
,
Sean McBride
,
Nadeem Riaz
…
See all similar
Cited by
46
Recombinant protein vaccines produced in insect cells
Authors:
Manon Cox
European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination
Authors:
Lawrence von Karsa
,
Marc Arbyn
,
Hugo De Vuyst
…
Costs of Introducing and Delivering HPV Vaccines in Low and Lower Middle Income Countries: Inputs for GAVI Policy on Introduction Grant Support to Countries
Authors:
Ann Levin
,
Susan Wang
,
Carol Levin
…
See all cited by